A monkey’s name on millions of blood reports
Every day, millions of blood reports around the world carry two letters that most people never think to question: Rh. The letters stand for rhesus, as in the rhesus macaque, a monkey of South Asia. How a monkey’s name ended up permanently attached to human blood is one of the great stories of twentieth-century medicine: a tale of a Nobel laureate, a careful experiment, a scientific twist, and a discovery that turned one of childbirth’s most feared killers into a preventable condition. It begins, as so much of blood science does, with Karl Landsteiner.
Landsteiner returns to the scene
By the late 1930s, Karl Landsteiner was already a legend. In 1901 he had discovered the ABO blood groups, the finding that human blood comes in types, and that mixing incompatible types causes red cells to clump and be destroyed. That insight made safe transfusion possible and earned him the Nobel Prize in 1930. But Landsteiner knew ABO was not the whole story: patients sometimes reacted badly to transfusions that were, on paper, perfectly ABO-matched. Something else had to be sitting on the surface of red cells, something nobody had yet named.
The decisive step came in 1940, when Landsteiner and Alexander S. Wiener, working in New York, injected rhesus macaque blood into rabbits and guinea pigs. The animals’ immune systems did what immune systems do: they made antibodies against the rhesus red cells. (It built on work Landsteiner had begun in 1937 with physician Philip Levine.)
The antigen that most humans shared
Then came the step that made history. Landsteiner and Wiener tested those rabbit antibodies against samples of human blood. The antibodies reacted with the red cells of most of the samples, but not all of them, meaning an antigen found in rhesus blood was also present on the red cells of most humans, while a minority apparently lacked it.
The antigen was named Rh, for rhesus, and humans were sorted into two camps: those whose cells carried it (Rh positive) and those whose did not (Rh negative). The ’+’ and ’−’ that decorate every blood group report to this day descend directly from that 1940 experiment.
The twist: the monkey antigen wasn’t quite the human antigen
Science, being science, had a revision in store. In the years that followed, researchers working out the details of the new blood group system (most notably through the Fisher–Race and Wiener nomenclatures) established that the antigen found on rhesus red cells and the antigen responsible for human Rh incompatibility, the D antigen, are not identical. They are related and cross-reacting, which is why the original experiment worked at all, but the human D antigen is its own molecule. Strictly speaking, the monkey antigen is now classified in a separate system (the “Landsteiner–Wiener” system, a small piece of historical irony), while the clinically crucial human antigen remains the D antigen of the Rh system.
By the time this was settled, the name had long since stuck. Laboratories, textbooks and medical records the world over were built on “Rh,” and the practical label outlived the scientific nicety. It remains one of medicine’s most familiar misnomers, and a reminder that names in science often record the journey of discovery rather than the destination.
From laboratory curiosity to clinical lifesaver
The discovery’s impact arrived in two waves. The first explained those long-mysterious transfusion reactions: some Rh negative patients who had received ABO-compatible blood developed fevers, jaundice and worse, because their immune systems (meeting the D antigen for the first time) learned to make anti-D that destroyed subsequent Rh+ transfusions. Matching the Rh factor, not just ABO, became standard practice, eliminating a major cause of transfusion danger.
The second wave was more poignant. Clinicians had long observed a devastating illness in newborns, babies born healthy-looking, then turning jaundiced and gravely ill, often in later children of mothers who had lost earlier infants the same way. With Rh understood, the mechanism fell into place: an Rh negative mother, carrying an Rh positive baby, could be sensitised to the D antigen around delivery. Her anti-D antibodies then threatened her Rh+ babies in later pregnancies, a condition called hemolytic disease of the fetus and newborn. The mother’s own immune system, in effect, was the disease.
Anti-D: turning a killer into a preventable condition
Understanding the mechanism pointed directly at the cure’s shape: if sensitisation could be blocked, the disease would never begin. In the 1960s, researchers developed anti-D immunoglobulin, a preparation of anti-D antibodies given to Rh negative mothers during pregnancy and after delivery. The injected antibodies clear any Rh+ fetal cells from the mother’s circulation before her immune system can mount its own response. Sensitisation is prevented; future pregnancies are protected. Introduced into routine care through the late 1960s, anti-D transformed hemolytic disease from a leading cause of newborn death into a largely preventable condition, one of the great public-health victories of the century, and one that quietly depends on blood donors, since anti-D is made from donated plasma.
Why the story still matters
The rhesus story is worth remembering for more than trivia. It shows how basic research (an immunologist, some rabbits, and monkey blood) ended up safeguarding every pregnancy and every transfusion. It reminds us that scientific names are fossils of discovery: “Rh” immortalises an experiment even though the antigen it names turned out to be distinctly human. And it explains why your blood report looks the way it does.
Want to go deeper? Read how the Rh system works in practice in the Rh factor, see where the system’s extremes live in rare blood types, and learn how + and − are passed down in blood group genetics. And if you are Rh negative, your blood carries the legacy of 1940, register as a donor and put it to work.